TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06361888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Description: Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel Plus Gemcitabine
Description: Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Study: NCT04663126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m
Study: NCT06306638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Photodynamic Therapy
Description: Undergo I-PDT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Photodynamic Therapy
Description: Undergo I-PDT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Photodynamic Therapy
Description: Undergo I-PDT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy
Study: NCT05273619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8, film-coated tablets, 10 mg
Description: 80 mg/day: 4 tablets (40 mg) twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets twice a day
Study: NCT06361888

Intervention type: DRUG
Group type: OTHER
Intervention: Surufatinib with Nab-paclitaxel, and Gemcitabine
Description: Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8
Study: NCT05339009

Intervention type: BIOLOGICAL
Intervention: BioADM determination in plasma
Description: BioADM determination in plasma
Study: NCT06124196

Intervention type: DEVICE
Intervention: wearable technology
Description: Three wearable devices
Study: NCT05524649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement 1
Description: Probiotic single strain formulation containing Bifidobacterium longum CECT7894 for 3 months 5 drops/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food Supplement 2
Description: Probiotic single strain formulation containing Pediococcus pentosaceus CECT8330 for 3 months 5 drops/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops/day for 3 months of sunflower oil
Study: NCT04703010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography-Near infrared spectroscopy
Description: Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychometric testing
Description: Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
Study: NCT05077553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI999 probiotic sachet
Description: Testing product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Blank
Study: NCT06257953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
Study: NCT06306638

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06306638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser: ML7710-PDT
Description: Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser: ML7710-PDT
Description: Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
Study: NCT05241821

Intervention type: PROCEDURE
Intervention: Mechanical thrombectomy
Description: Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.

Intervention type: DRUG
Intervention: Thrombolytic Agent
Description: Drug aimed to dissolve thrombus affecting the cerebral circulation
Study: NCT05559268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 MG/ML Injectable Solution [Prolia]
Description: 1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after TKA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
Study: NCT05593653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 20mg taken at bedtime for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken at bedtime for 4 weeks
Study: NCT05524766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7 Treatment
Description: Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
Study: NCT05505383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
Study: NCT04820296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solution-Oriented Approach
Description: First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
Study: NCT05376761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
Study: NCT05116371

Intervention type: DRUG
Intervention: 150 mcg levonorgestrel/30 mcg ethinyl estradiol
Description: concurrent use of COC with Nexplanon

Intervention type: DRUG
Intervention: 150 mcg levonorgestrel/30 mcg ethinyl estradiol
Description: concurrent use of COC with Nexplanon
Study: NCT04826484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 133 miligrams per 10 milliliter injection
Description: Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Local wound infiltration with 0.25% bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Local wound infiltration with 0.25% bupivacaine.
Study: NCT06443463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
Study: NCT06573567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
Study: NCT06573554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Contact Cast
Description: Knee High Fiber Glass Total contact Cast

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Slab
Description: Posterior Slab Knee high non walking
Study: NCT05554354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06642454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz.
Study: NCT05946213

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06650579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given abiraterone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given abiraterone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography
Description: Undergo CCTA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography
Description: Undergo CCTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given IM or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given prednisone

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study: NCT05930483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive delivered groceries

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in ¡Vida! program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in ¡Vida! program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in ¡Vida! program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in ¡Vida! program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in ¡Vida! program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in ¡Vida! program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06157983

Intervention type: OTHER
Intervention: measurement of lipoprotein(a)
Description: Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
Study: NCT05556460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragonFly-T Transcatheter Tricuspid Valve Repair System
Description: To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Subjects will continue to be managed on medical therapy, per physician discretion
Study: NCT05933330

Intervention type: OTHER
Intervention: Brain MRI
Description: All included patients receive an MRI of the brain
Study: NCT05074524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
Study: NCT05704270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain adaptive cognitive training
Description: The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic cognitive training with no difficulty change
Description: The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
Study: NCT06517498

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be conducted
Study: NCT05377112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802v1
Description: SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
Study: NCT06101147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group